National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cabozantinib (Cabometyx®) is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

NCPE Assessment Process Ongoing
Rapid review received 20/03/2017
Rapid review completed 25/04/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 02/05/2017
Pre-submission consultation with Applicant 17/07/2017
Submission received from Applicant 03/11/2017
Current status HTA submission received